Molecular basis of agonism and antagonism in the oestrogen receptor
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Oestrogens are involved in the growth, development and homeostasis of a number of tissues. The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER). Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of molecular events culminating in the activation or repression of target genes. Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery. Here we report the crystal structures of the LBD of ER in complex with the endogenous oestrogen, 17beta-oestradiol, and the selective antagonist raloxifene, at resolutions of 3.1 and 2.6 A, respectively. The structures provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties. Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes. In addition, each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We previously found that the full-length ERα dimer forms a symmetric tail-to-tail dimer in the ERα/SRC-3/p300 complex (Yi et al., 2015), consistent with the nature of palindromic DNA binding sequence, symmetric X-ray crystal structures of the ERα LBD (Brzozowski et al., 1997) and DBD dimers (Schwabe et al., 1993).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
In the citing paper
“the AR LBD interacts weakly with LXXLL motif-containing coactivators, such as SRCs, (Brzozowski et al., 1997; Dubbink et al., 2006; He et al., 2004; He et al., 1999; Matias et al., 2000; Nadal et al., 2017).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475 · cited 1×
“Data were integrated and reduced using the programs DENZO and SCALEPAC”
MethodPROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions
Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/8.2.127 · Cited by 5,690
MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS
Tsai, M.-J., & O'Malley, B. W. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.002315 · Cited by 2,932 · cited 1×
“The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER”
BackgroundThe estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,220 · cited 1×
“The ER LBDs are arranged as non-crystallographic dimers within both the E 2 and RAL complex crystals in a manner consistent with both the oligomeric state of liganded ER in solutio”
BackgroundCrystal structure of the ligand-binding domain of the human nuclear receptor RXR-α
Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/375377a0 · Cited by 1,177 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundCrystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid
Renaud, J.-P., Rochel, N., Ruff, M., Vivat, V., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/378681a0 · Cited by 1,097 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundA canonical structure for the ligand-binding domain of nuclear receptors
Wurtz, J.-M., Bourguet, W., Renaud, J.-P., Vivat, V., Chambon, P., Moras, D., & Gronemeyer, H. (1996) · Nature Structural Biology · doi:10.1038/nsb0196-87 · Cited by 985 · cited 1×
“, and emphasizes the universal nature of this fold within this receptor superfamil”
Background
Cited by
Items 201–300 of 1,012
Montano, M. M., Ekena, K., Delage-Mourroux, R., Chang, W., Martini, P., & Katzenellenbogen, B. S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6947 · Cited by 296
Ligand binding and nuclear receptor evolution
Escriva, H., Delaunay, F., & Laudet, V. (2000) · BioEssays · doi:10.1002/1521-1878(200008)22:8<717::aid-bies5>3.0.co;2-i · Cited by 296
Darbre, P. D. (2006) · Journal of Applied Toxicology · doi:10.1002/jat.1135 · Cited by 295
“This may explain why the only amino acid residue common to the binding of both physiological oestrogens (Brzozowski et al., 1997; Tanenbaum et al., 1998) and metalloestrogens (Stoica et al.”
BackgroundInfluentialVitamin D Receptor Signaling Mechanisms: Integrated Actions of a Well-Defined Transcription Factor
Carlberg, C., & Campbell, M. J. (2013) · Steroids · doi:10.1016/j.steroids.2012.10.019 · Cited by 293
“non-polar amino acids and thereby complements the lipophilic character of the ligands [18].”
Transcriptional Repression by Nuclear Hormone Receptors
Hu, X., & Lazar, M. A. (2000) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(99)00215-5 · Cited by 292
Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer
Jordan, V. C. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706399 · Cited by 292
“As it turned out, this was a good strategic decision, as it has taken nearly 30 years to achieve partial success, with the structure of the OER ligand binding domain complexed with oestradiol and raloxifene being solved in 1997 (Brzozowski et al., 1997).”
BackgroundNuclear receptors: integration of multiple signalling pathways through phosphorylation
Rochette-Egly, C. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(02)00115-8 · Cited by 291
Greschik, H., Wurtz, J.-M., Sanglier, S., Bourguet, W., van Dorsselaer, A., Moras, D., & Renaud, J.-P. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00444-6 · Cited by 291
Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions
Rodriguez, A. C., Blanchard, Z., Maurer, K. A., & Gertz, J. (2019) · Hormones and Cancer · doi:10.1007/s12672-019-0358-9 · Cited by 291
Chen, D., Riedl, T., Washbrook, E., Pace, P. E., Coombes, R. C., Egly, J.-M., & Ali, S. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00004-3 · Cited by 290
Molecular Mechanisms of Estrogen Action: Selective Ligands and Receptor Pharmacology
Katzenellenbogen, B. S., Choi, I., Delage-Mourroux, R., Ediger, T. R., Martini, P. G. V., Montano, M., Sun, J., Weis, K., & Katzenellenbogen, J. A. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00104-7 · Cited by 289
Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects
di Masi, A., Marinis, E. D., Ascenzi, P., & Marino, M. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.04.002 · Cited by 288
Nutritional implications of ginger: chemistry, biological activities and signaling pathways
Kiyama, R. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108486 · Cited by 288
Tamoxifen Resistance in Breast Cancer
Chang, M.-S. (2012) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2012.20.3.256 · Cited by 285
“Analysis of the E2-ER LBD complex showed that helix 12 is packed against helix 3, 5/6, and helix 11, sealing the ligand binding pocket like a lid (Brzozowski et al., 1997).”
BackgroundJakacka, M., Ito, M., Weiss, J., Chien, P.-Y., Gehm, B. D., & Jameson, J. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008384200 · Cited by 284
Nuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
“In the case of raloxifene binding, H12 is placed in such a position so as to physically block NR box binding (Brzozowski et al., 1997; Shiau et al., 1998); in the case of ICI 182,780 binding, the long aliphatic extension of this compound itself exits the LBP entryway and folds along the coactivator binding groove, thu…”
BackgroundInfluentialMultiplexed microsphere-based flow cytometric assays
Kellar, K. L., & Iannone, M. A. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00922-0 · Cited by 282
“In fact, these ligands stabilize a protein conformation where the AF-2 helix of the LBD physically occludes the coactivator binding cleft [95–97].”
BackgroundSelective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance
Lewis, J. S., & Jordan, V. C. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2005.02.028 · Cited by 281
Chemosensitization and Radiosensitization of Tumors by Plant Polyphenols
Garg, A. K., Buchholz, T. A., & Aggarwal, B. B. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.1630 · Cited by 278
“Genistein is a soy-derived isoflavone that acts as a tyrosine kinase inhibitor and has a structure with an affinity for the estrogen receptor and androgen-mediated pathways (33).”
BackgroundA high-affinity subtype-selective agonist ligand for the thyroid hormone receptor
Chiellini, G., Apriletti, J. W., Yoshihara, H. A., Baxter, J. D., Ribeiro, R. C. J., & Scanlan, T. S. (1998) · Chemistry & Biology · doi:10.1016/s1074-5521(98)90168-5 · Cited by 278
Svensson, S. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg456 · Cited by 278
Top, S., Vessières, A., Cabestaing, C., Laïos, I., Leclercq, G., Provot, C., & Jaouen, G. (2001) · Journal of Organometallic Chemistry · doi:10.1016/s0022-328x(01)00953-6 · Cited by 277
Molecular Mechanisms in Spermatogenesis
(2008) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-09597-4 · Cited by 276
Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis
Wu, H., Chen, Y., Liang, J., Shi, B., Wu, G., Zhang, Y., Wang, D., Li, R., Yi, X., Zhang, H., et al. (2005) · Nature · doi:10.1038/nature04225 · Cited by 273
Zhu, B. T., Han, G.-Z., Shim, J.-Y., Wen, Y., & Jiang, X.-R. (2006) · Endocrinology · doi:10.1210/en.2006-0113 · Cited by 271
Multiple aspects of mineralocorticoid selectivity
Farman, N., & Rafestin-Oblin, M.-E. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.2.f181 · Cited by 268
“The crystal structure of several nuclear receptor ligand binding domains is now available, revealing a common fold with 11–12 a-helices (numbered H1-H12) and 1 b-turn arranged as an antiparallel a-helical “sandwich” in a 3-layer structure (17, 19, 93, 104, 113, 116, 119).”
BackgroundHu, J., Hu, B., Wang, M., Xu, F., Miao, B., Yang, C.-Y., Wang, M., Liu, Z., Hayes, D. F., Chinnaswamy, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01572 · Cited by 268
LIGAND CONTROL OF COREGULATOR RECRUITMENT TO NUCLEAR RECEPTORS
Nettles, K. W., & Greene, G. L. (2005) · Annual Review of Physiology · doi:10.1146/annurev.physiol.66.032802.154710 · Cited by 268
Self-citationFrom estrogen to androgen receptor: A new pathway for sex hormones in prostate
Yeh, S., Miyamoto, H., Shima, H., & Chang, C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5527 · Cited by 267
Advances in Platinum Chemotherapeutics
Harper, B. W., Krause‐Heuer, A. M., Grant, M. P., Manohar, M., Garbutcheon‐Singh, K. B., & Aldrich‐Wright, J. R. (2010) · Chemistry – A European Journal · doi:10.1002/chem.201000148 · Cited by 267
Mortensen, D. S., Rodriguez, A. L., Carlson, K. E., Sun, J., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010211u · Cited by 267
Oestrogenic and androgenic activity of triclosan in breast cancer cells
Gee, R. H., Charles, A., Taylor, N., & Darbre, P. D. (2008) · Journal of Applied Toxicology · doi:10.1002/jat.1316 · Cited by 266
“1) together with other hydrophobic interactions which then stabilises a receptor conformation in which H12 is aligned across the entrance to the LBD such that coactivator recruitment is facilitated (Brzozowski et al., 1997).”
BackgroundAndrogen receptor as a target in androgen-independent prostate cancer
Balk, S. P. (2002) · Urology · doi:10.1016/s0090-4295(02)01593-5 · Cited by 264
Estrogen Receptor Signaling in the Immune System
Chakraborty, B., Byemerwa, J., Krebs, T., Lim, F., Chang, C.-Y., & McDonnell, D. P. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac017 · Cited by 263
Htun, H., Holth, L. T., Walker, D., Davie, J. R., & Hager, G. L. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.2.471 · Cited by 261
“Antagonist ligands, on the other hand, induce a different receptor conformation that interferes with the ability of the receptor to bind to DNA or alternatively to prevent formation of a productive transcriptional preinitiation complex by abrogating its interaction with the general transcription factors and/or transcr…”
BackgroundInfluentialComparative QSAR Analysis of Estrogen Receptor Ligands
Gao, H., Katzenellenbogen, J. A., Garg, R., & Hansch, C. (1999) · Chemical Reviews · doi:10.1021/cr980018g · Cited by 260
Aluminium, antiperspirants and breast cancer
Darbre, P. D. (2005) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2005.06.001 · Cited by 260
Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor PPARγ
Uppenberg, J., Svensson, C., Jaki, M., Bertilsson, G., Jendeberg, L., & Berkenstam, A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.47.31108 · Cited by 260
Phosphorylation of Human Estrogen Receptor α by Protein Kinase A Regulates Dimerization
Chen, D., Pace, P. E., Coombes, R. C., & Ali, S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1002 · Cited by 260
“Extensive deletional and mutational analyses have shown that homodimerization by ERa is mediated by sequences in the DBD and the LBD, and determination of the crystal structures of the ERa DNA and LBDs have further delineated the amino acid residues involved in dimerization (17, 75).”
BackgroundDesign and Synthesis of Aryl Diphenolic Azoles as Potent and Selective Estrogen Receptor-β Ligands
Malamas, M. S., Manas, E. S., McDevitt, R. E., Gunawan, I., Xu, Z. B., Collini, M. D., Miller, C. P., Dinh, T., Henderson, R. A., Keith, J. C., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049719y · Cited by 260
Tamoxifen, Raloxifene, and the Prevention of Breast Cancer*
Jordan, V. C., & Morrow, M. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0368 · Cited by 258
“The crystallization of the ligand-binding domain of the ER with estradiol and raloxifene has provided an important insight into the conformational changes that occur in the receptor (104) liganded with an estrogen or an antiestrogen, respectively.”
BackgroundFernandes, I., Bastien, Y., Wai, T., Nygard, K., Lin, R., Cormier, O., Lee, H. S., Eng, F., Bertos, N. R., Pelletier, N., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00014-5 · Cited by 255
“Crystal structures of agonist- and antagonistbound LBDs have revealed conserved helical structures (Bourget et al., 1995; Renaud et al., 1995; Wagner et al., 1995; Brzozowski et al., 1997).”
BackgroundChmelar, R., Buchanan, G., Need, E. F., Tilley, W., & Greenberg, N. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22365 · Cited by 255
Hall, J. M. (2002) · Molecular Endocrinology · doi:10.1210/me.16.3.469 · Cited by 253
The Dynamic Structure of the Estrogen Receptor
Kumar, R., Zakharov, M. N., Khan, S. H., Miki, R., Jang, H., Toraldo, G., Singh, R., Bhasin, S., & Jasuja, R. (2011) · Journal of Amino Acids · doi:10.4061/2011/812540 · Cited by 252
“In an agonistbound form, ERα is spatially organized in a three-layered structure with helices 4, 5, 6, 8, and 9 lining up on one side by H1 and H3, and on the other side are helices 7, 10, and 11 [24].”
BackgroundThe Actions and Interactions of Sex Steroids and Growth Factors/Cytokines on the Skeleton
Spelsberg, T. C. (1999) · Molecular Endocrinology · doi:10.1210/me.13.6.819 · Cited by 251
“While SERMs bind the receptor at the same site and often with the same affinity as E, they induce different conformational changes in the receptor molecule which, in turn, alters which transcriptional activation domains on the ER molecule will be active (53).”
BackgroundKinetic analysis of estrogen receptor/ligand interactions
Rich, R. L., Hoth, L. R., Geoghegan, K. F., Brown, T. A., LeMotte, P. K., Simons, S. P., Hensley, P., & Myszka, D. G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.142288199 · Cited by 251
Development of subtype-selective oestrogen receptor-based therapeutics
Nilsson, S., Koehler, K. F., & Gustafsson, J.-Å. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3551 · Cited by 249
Self-citationBenninghoff, A. D., Bisson, W. H., Koch, D. C., Ehresman, D. J., Kolluri, S. K., & Williams, D. E. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfq379 · Cited by 248
“3) (Brzozowski et al., 1997; Marchand-Geneste et al., 2006).”
MethodDesign and Structure of Stapled Peptides Binding to Estrogen Receptors
Phillips, C., Roberts, L. R., Schade, M., Bazin, R., Bent, A., Davies, N. L., Moore, R., Pannifer, A. D., Pickford, A. R., Prior, S. H., et al. (2011) · Journal of the American Chemical Society · doi:10.1021/ja202946k · Cited by 247
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis
Shang, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1879 · Cited by 246
Biological Role of Estrogen and Estrogen Receptors
Nilsson, S., & Gustafsson, J.-Å. (2002) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230290771438 · Cited by 244
Self-citationComparative Analyses of Mechanistic Differences Among Antiestrogens1
Wijayaratne, A. L., Nagel, S. C., Paige, L. A., Christensen, D. J., Norris, J. D., Fowlkes, D. M., & McDonnell, D. P. (1999) · Endocrinology · doi:10.1210/endo.140.12.7164 · Cited by 244
Carboranes in drug discovery, chemical biology and molecular imaging
Marfavi, A., Kavianpour, P., & Rendina, L. M. (2022) · Nature Reviews Chemistry · doi:10.1038/s41570-022-00400-x · Cited by 244
Fink, B. E., Mortensen, D. S., Stauffer, S. R., Aron, Z. D., & Katzenellenbogen, J. A. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80037-4 · Cited by 244
A comparison of transcriptional activation by ERα and ERβ
Cowley, S. M., & Parker, M. G. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(99)00055-2 · Cited by 243
Estrogen Receptors: New Directions in the New Millennium
Hewitt, S. C., & Korach, K. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00087 · Cited by 240
Kubinyi, H., Hamprecht, F. A., & Mietzner, T. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970732a · Cited by 240
Structural studies on nuclear receptors
Renaud, J. P., & Moras*, D. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000656 · Cited by 238
Christopoulos, A., Changeux, J.-P., Catterall, W. A., Fabbro, D., Burris, T. P., Cidlowski, J. A., Olsen, R. W., Peters, J. A., Neubig, R. R., Pin, J.-P., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.008862 · Cited by 238
“The LBD is a globular domain composed of a three-layered a -helical “ sandwich ” (Brzozowski et al., 1997; Moras and Gronemeyer, 1998; Savkur and Burris, 2004).”
BackgroundThe Drosophila Orphan Nuclear Receptor DHR38 Mediates an Atypical Ecdysteroid Signaling Pathway
Baker, K. D., Shewchuk, L. M., Kozlova, T., Makishima, M., Hassell, A., Wisely, B., Caravella, J. A., Lambert, M. H., Reinking, J. L., Krause, H., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00420-3 · Cited by 238
Subnuclear Trafficking of Estrogen Receptor-α and Steroid Receptor Coactivator-1
Stenoien, D. L., Mancini, M. G., Patel, K., Allegretto*, E. A., Smith, C. L., & Mancini, M. A. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.4.0436 · Cited by 237
Chen, D., Washbrook, E., Sarwar, N., Bates, G. J., Pace, P. E., Thirunuvakkarasu, V., Taylor, J., Epstein, R. J., Fuller-Pace, F. V., Egly, J.-M., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205420 · Cited by 236
“Recent studies have further demonstrated that anti-estrogen binding results in helix 12 occupying the co-activator binding site, thereby preventing co-activator recruitment (Brzozowski et al., 1997; Shiau et al., 1998).”
BackgroundStructural Basis for an Unexpected Mode of SERM-Mediated ER Antagonism
Wu, Y.-L., Yang, X., Ren, Z., McDonnell, D. P., Norris, J. D., Willson, T. M., & Greene, G. L. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.014 · Cited by 232
“(A) Overall structures of E2- (Brzozowski et al., 1997), OHT- (Shiau et al.”
BackgroundSelf-citationKian Tee, M., Rogatsky, I., Tzagarakis-Foster, C., Cvoro, A., An, J., Christy, R. J., Yamamoto, K. R., & Leitman, D. C. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-06-0360 · Cited by 230
Cross-talk between glucocorticoid receptor and AP-1
Herrlich, P. (2001) · Oncogene · doi:10.1038/sj.onc.1204388 · Cited by 230
“…ligand binding domain whose ligand interaction appears to determine the accessibility of the transactivation domain AF-2 (Bourguet et al., 1995; Brzozowski et al., 1997; Shiau et al., 1998; Hu and Lazar, 1999), and an N-terminal domain which carries the ligand-independent AF-1 (see review by…”
BackgroundEstrogen Receptors as Therapeutic Targets in Breast Cancer
Ariazi, E. A., & Jordan, V. C. (2008) · Methods and Principles in Medicinal Chemistry · doi:10.1002/9783527623297.ch5 · Cited by 230
Progesterone Receptor Signaling Mechanisms
Grimm, S. L., Hartig, S. M., & Edwards, D. P. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.06.020 · Cited by 229
Estrogen receptor function and regulation in fish and other vertebrates
Nelson, E. R., & Habibi, H. R. (2013) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2013.03.032 · Cited by 229
Lavery, D. N., & Mcewan, I. J. (2005) · Biochemical Journal · doi:10.1042/bj20050872 · Cited by 227
Environmental oestrogens, cosmetics and breast cancer
Darbre, P. D. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.09.007 · Cited by 227
The Drosophila ecdysone receptor (EcR) Gene Is Required Maternally for Normal Oogenesis
Carney, G. E., & Bender, M. (2000) · Genetics · doi:10.1093/genetics/154.3.1203 · Cited by 226
Estrogen Receptor Function: Impact on the Human Endometrium
Yu, K., Huang, Z.-Y., Xu, X.-L., Li, J., Fu, X.-W., & Deng, S.-L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.827724 · Cited by 225
Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis
Yeldandi, A. V., Rao, M. S., & Reddy, J. K. (2000) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(99)00234-1 · Cited by 225
Discrimination between NL1- and NL2-Mediated Nuclear Localization of the Glucocorticoid Receptor
Savory, J. G. A., Hsu, B., Laquian, I. R., Giffin, W., Reich, T., Haché, R. J. G., & Lefebvre, Y. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1025 · Cited by 222
Leduc, A.-M., Trent, J. O., Wittliff, J. L., Bramlett, K. S., Briggs, S. L., Chirgadze, N. Y., Wang, Y., Burris, T. P., & Spatola, A. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934759100 · Cited by 222
Estrogens and environmental estrogens
Tapiero, H., Nguyen Ba, G., & Tew, K. D. (2002) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(01)00155-x · Cited by 222
NAKAJIMA, M., FUKAMI, T., YAMANAKA, H., HIGASHI, E., SAKAI, H., YOSHIDA, R., KWON, J., MCLEOD, H., & YOKOI, T. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.05.012 · Cited by 222
Sabo-Attwood, T., Kroll, K. J., & Denslow, N. D. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.12.007 · Cited by 222
The pleiotropic functions of peroxisome proliferator-activated receptor γ
Debril, M.-B., Renaud, J.-P., Fajas, L., & Auwerx, J. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090000145 · Cited by 220
“dimerization interface in RXR [136], ER [133], and”
BackgroundOestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state
Green, K. A., & Carroll, J. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2211 · Cited by 220
Coactivator Binding Promotes the Specific Interaction Between Ligand and the Pregnane X Receptor
Watkins, R. E., Davis-Searles, P. R., Lambert, M. H., & Redinbo, M. R. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00795-2 · Cited by 220
Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
Rani, A., Stebbing, J., Giamas, G., & Murphy, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00245 · Cited by 219
“Both the AF1 and AF2 domains are crucial, but the AF2 activation serves as the binding region for coactivators and corepressors (48, 49).”
BackgroundSerum Estradiol Level and Risk of Breast Cancer During Treatment With Raloxifene
Cummings, S. R. (2002) · JAMA · doi:10.1001/jama.287.2.216 · Cited by 219
“This is consistent with the belief that raloxifene reduces breast cancer risk by blocking the effect of estradiol on the breast.(5,6) Since tamoxifen may act by a similar mechanism, the interaction between endogenous estradiol and the effect of tamoxifen on breast cancer risk deserves study.”
ResultBledsoe, R. K., Madauss, K. P., Holt, J. A., Apolito, C. J., Lambert, M. H., Pearce, K. H., Stanley, T. B., Stewart, E. L., Trump, R. P., Willson, T. M., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504098200 · Cited by 218
Kraichely, D. M., Sun, J., Katzenellenbogen, J. A., & Katzenellenbogen, B. S. (2000) · Endocrinology · doi:10.1210/endo.141.10.7698 · Cited by 217
“Crystallographic studies of the ligand-binding domains of ERa (31, 32) and ERb (33) have revealed that both have a similar overall structure, although the conformation of portions of this domain changes in response to ligands having different biological character (i.”
BackgroundPPARs and lipid ligands in inflammation and metabolism
Harmon, G. S., Lam, M. T., & Glass, C. K. (2011) · Chemical Reviews · doi:10.1021/cr2001355 · Cited by 216
Taylor, C. K., Levy, R. M., Elliott, J. C., & Burnett, B. P. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.2009.00213.x · Cited by 216
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance
Katzenellenbogen, J. A., Mayne, C. G., Katzenellenbogen, B. S., Greene, G. L., & Chandarlapaty, S. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0001-z · Cited by 216
Self-citationNagy, L., Szanto, A., Szatmari, I., & Széles, L. (2012) · Physiological Reviews · doi:10.1152/physrev.00004.2011 · Cited by 216
Matsushima, A., Liu, X., Okada, H., Shimohigashi, M., & Shimohigashi, Y. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.0901819 · Cited by 215
“…ERβ ligand-binding pocket must damage the ERβ-LBD activation conformation, in which the α-helix 12 (H12) in LBD is Environmental Health Perspectives • volume 118 | number 9 | September 2010 1271 positioned to recruit the coactivator proteins conformation (Brzozowski et al. 1997; Ruff et al. 2000).”
BackgroundLee, S.-K., Anzick, S. L., Choi, J.-E., Bubendorf, L., Guan, X.-Y., Jung, Y.-K., Kallioniemi, O. P., Kononen, J., Trent, J. M., Azorsa, D., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.48.34283 · Cited by 213
X-ray Crystal Structure of the Liver X Receptor β Ligand Binding Domain
Williams, S., Bledsoe, R. K., Collins, J. L., Boggs, S., Lambert, M. H., Miller, A. B., Moore, J., McKee, D. D., Moore, L., Nichols, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302260200 · Cited by 212
Estrogen Receptors: How Do They Control Reproductive and Nonreproductive Functions?
Muramatsu, M., & Inoue, S. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2214 · Cited by 212
Lu, D., Kiriyama, Y., Lee, K. Y., & Giguère, V. (2001) · PubMed · Cited by 212
Zhang, X., Bolt, M., Guertin, M. J., Chen, W., Zhang, S., Cherrington, B. D., Slade, D. J., Dreyton, C. J., Subramanian, V., Bicker, K. L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203280109 · Cited by 211
“Depletion of PAD4 (PAD4 KD) from MCF-7 cells was described (3).”
BackgroundMethodKeay, J., Bridgham, J. T., & Thornton, J. W. (2006) · Endocrinology · doi:10.1210/en.2006-0363 · Cited by 211
“17 Estradiol is shown surrounded by the residues at positions known to line the ligand-binding pocket in the human ER (30, 31).”
BackgroundMethodKumar, R., & Thompson, E. B. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0258 · Cited by 210
Cheskis, B. J., Greger, J. G., Nagpal, S., & Freedman, L. P. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21253 · Cited by 210
“An additional helix required for ligand-dependent transcriptional activation (AF2) resides at the C terminus of the LBD and adopts different positions depending on the presence or absence of ligands (Brzozowski et al., 1997).”
BackgroundStructural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor
Bohl, C. E., Miller, D. D., Chen, J., Bell, C. E., & Dalton, J. T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507464200 · Cited by 210
Metadata
- Authors
- Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M.
- Affiliations
- University of York (GB)
- Karo Pharma (Sweden) (SE)
- University of Chicago (US)
- Corresponding author
- Hubbard, Roderick E.
- ORCID
- Venue
- Nature
- Published
- 1997-10
- Volume
- 389
- Issue
- 6652
- Pages
- 753-758
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2101738855
- Cited by
- 3,355
- References
- 29
- Citations by year
- 2026: 49 · 2025: 55 · 2024: 55 · 2023: 61 · 2022: 62 · 2021: 91 · 2020: 55 · 2019: 75 · 2018: 73 · 2017: 65 · 2016: 72 · 2015: 74 · 2014: 94 · 2013: 105 · 2012: 104
- FWCI
- 94.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- oestrogen receptor, ligand-binding domain, estradiol, raloxifene, selective estrogen receptor modulators, crystal structure, transcriptional regulation
- MeSH terms
- Binding Sites, Estradiol, Estrogen Antagonists, Humans, Models, Molecular, Piperidines, Protein Conformation, Receptors, Estrogen, Crystallography, X-Ray, Raloxifene Hydrochloride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.